Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.78 |
| ▸ | KDR | P35968 | 5/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827329 | 0.89 | BRAF (0.77) | BRAFKDRCYP2C9 | |
| SCHEMBL823676 | 0.88 | BRAF (1.00) | BRAFKDR | |
| SCHEMBL826636 | 0.86 | BRAF (0.78) | BRAFKDRCYP2C9 | |
| SCHEMBL2194047 | 0.83 | BRAF (0.57) | BRAFKDRCYP2C9 | |
| SCHEMBL2334105 | 0.83 | KDR (0.55) | BRAFKDR | |
| SCHEMBL2862024 | 0.82 | BRAF (0.56) | BRAFKDRCYP2C9 | |
| SCHEMBL2191832 | 0.81 | BRAF (0.56) | BRAFKDRCYP2C9 | |
| SCHEMBL823631 | 0.81 | BRAF (1.00) | BRAFKDRCYP2C9 | |
| SCHEMBL2192169 | 0.81 | BRAF (0.54) | BRAFKDRCYP2C9 | |
| SCHEMBL823627 | 0.80 | BRAF (0.84) | BRAFKDRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497274-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8143258-B2 | Benzothiazole compounds useful for Raf inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| EP-2358689-A1 | Benzothiazole derivatives as anticancer agents | Takeda Pharmaceutical Company Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885KDR 1130/4885CYP2C9 1851/4885 |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885KDR 1130/4885CYP2C9 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.